 Prodrugs
"Prodrugs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
| Descriptor ID |
D011355
|
| MeSH Number(s) |
D26.675
|
| Concept/Terms |
Prodrugs- Prodrugs
- Pro-Drugs
- Pro Drugs
- Drug Precursors
- Precursors, Drug
|
Below are MeSH descriptors whose meaning is more general than "Prodrugs".
Below are MeSH descriptors whose meaning is more specific than "Prodrugs".
This graph shows the total number of publications written about "Prodrugs" by people in this website by year, and whether "Prodrugs" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 1 | 0 | 1 | | 1989 | 0 | 1 | 1 | | 1992 | 2 | 0 | 2 | | 1993 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 1999 | 0 | 5 | 5 | | 2000 | 0 | 2 | 2 | | 2001 | 2 | 2 | 4 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 2 | 3 | | 2005 | 3 | 0 | 3 | | 2008 | 1 | 1 | 2 | | 2009 | 2 | 0 | 2 | | 2012 | 1 | 1 | 2 | | 2013 | 2 | 0 | 2 | | 2016 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Prodrugs" by people in Profiles.
-
Brantley E, Callero MA, Berardi DE, Campbell P, Rowland L, Zylstra D, Amis L, Yee M, Simian M, Todaro L, Loaiza-Perez AI, Soto U. AhR ligand Aminoflavone inhibits a6-integrin expression and breast cancer sphere-initiating capacity. Cancer Lett. 2016 06 28; 376(1):53-61.
-
Dassopoulos T, Dubinsky MC, Bentsen JL, Martin CF, Galanko JA, Seidman EG, Sandler RS, Hanauer SB. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther. 2014 Jan; 39(2):163-75.
-
Hasegawa U, van der Vlies AJ, Wandrey C, Hubbell JA. Preparation of well-defined ibuprofen prodrug micelles by RAFT polymerization. Biomacromolecules. 2013 Sep 09; 14(9):3314-20.
-
Moysan E, Bastiat G, Benoit JP. Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications. Mol Pharm. 2013 Feb 04; 10(2):430-44.
-
van der Vlies AJ, Hasegawa U, Hubbell JA. Reduction-sensitive tioguanine prodrug micelles. Mol Pharm. 2012 Oct 01; 9(10):2812-8.
-
Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009 May 13; 2:20.
-
Arrighi I, Mark S, Alvisi M, von Rechenberg B, Hubbell JA, Schense JC. Bone healing induced by local delivery of an engineered parathyroid hormone prodrug. Biomaterials. 2009 Mar; 30(9):1763-71.
-
Rosner GL, Panetta JC, Innocenti F, Ratain MJ. Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther. 2008 Sep; 84(3):393-402.
-
Curado S, Stainier DY, Anderson RM. Nitroreductase-mediated cell/tissue ablation in zebrafish: a spatially and temporally controlled ablation method with applications in developmental and regeneration studies. Nat Protoc. 2008; 3(6):948-54.
-
Rorick-Kehn LM, Perkins EJ, Knitowski KM, Hart JC, Johnson BG, Schoepp DD, McKinzie DL. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J Pharmacol Exp Ther. 2006 Feb; 316(2):905-13.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|